期刊文献+

(3R)-2-羧乙基-3-氰基-5-甲基己酸乙酯水解酶产生菌的筛选与产酶条件优化 被引量:1

Strain Screening and Culture Condition Optimization for the Enantioselectively Hydrolysis of(3R)-2-Carboxyethyl-3-Cyano-5-Methylhexanoic Acid Ethyl Ester
原文传递
导出
摘要 以2-羧乙基-3-氰基-5-甲基己酸乙酯为唯一碳源,采用手性气相法检测,筛选到一株能产对映选择性水解酶的假单胞菌Pseudomonas CGMCC No.4184。该菌产的水解酶能优先水解R型底物产生(3R)-2-羧乙基-3-氰基-5-甲基己酸,产物对映体过量值达到90%以上。对菌株Pseudomonas CGMCC No.4184的产酶条件进行了研究,结果表明该菌产酶最适温度为30℃,最适pH为7.4。通过单因素试验、Plackett-Burman试验和响应面法研究并优化了产酶培养基组成,使酶活提高到33.43 U/L,比初始酶活(15.92 U/L)提高了2.1倍。利用静息细胞催化水解底物,当底物浓度和静息细胞干重分别为5 g/L和8 g/L时,在pH 7.4的磷酸缓冲液中反应48 h(温度30℃,摇床转速200 r/min),转化率为56.3%,底物对映体过量值达到98.3%,较好地实现了拆分制备(3S)-2-羧乙基-3-氰基-5-甲基己酸乙酯的目标。 Using(R,S)-2-carboxyethyl-3-cyano-5-methyl-hexanoic acid ethylester(rac-CCMAE) as sole carbon source,Pseudomonas sp.CGMCC No.4184 was isolated which can enantioselectively hydrolyze(R)-CCMAE to(3R)-2-carboxyethyl-3-cyano-5-methylhexanoic acid(3R-CCMA) with eep of over 90%.The optimal temperature and pH for the production of hydrolase by Pseudomonas CGMCC No.4184 were 30℃ and 7.4.Single-factor experiment,Plackett-Burman design and response surface methodology were applied subsequently to optimize the fermentation medium.After optimization,the enzyme activity increased from 15.92U/L to 33.43 U/L(about 2.1 fold).By using resting cell catalysis system,(S)-CCMAE were successfully prepared with the conversion of 56.3% and ees of 98.3% after 48 h under the condition of 5g/L CCMAE,8g/L(cell dry weight) resting cells,20ml 0.1mol/L phosphate buffer(pH 7.4),30℃ and 200r/min.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2011年第5期86-93,共8页 China Biotechnology
基金 国家自然科学基金重点项目(20936002,21076187) 国家“863”计划(2010AA101502) 国家“973”计划(2009CB724706,2011CB710805) 国家科技支撑计划重点项目(2008BAI63B07)资助项目
关键词 2-羧乙基-3-氰基-5-甲基己酸乙酯 假单胞菌 对映选择性 静息细胞 (R, S )-2-carboxyethyl-3-cyano-5-methylhexanoic acid ethylester PseudomonasEnantioselective Resting cells
  • 相关文献

参考文献19

  • 1Lauria-Horner B A, Pohl R B. Pregabalin: a new anxiolytic. Expert Opinion on Investigational Drugs, 2003, 12(4) :663-672.
  • 2Selak I. Pregabalin (Pfizer). Curr Opin Investig Drugs, 2001, 2 (6) :828-834.
  • 3Sammis G M, Jacobsen E N. Highly enantioselective, catalytic conjugate addition of cyanide to alpha, beta-unsaturated Imides. Journal of the American Chemical Society, 2003, 125 (15) :4442- 4443.
  • 4Burk M J, de Koning P D, Grote T M, et al. An enantioselective synthesis of (S)-( + )-3-amino-methyl-5-methylhexanoic acid via asymmetric hydrogenation. Journal of Organic Chemistry, 2003, 68(14) :5731-5734.
  • 5Yuen P W, Kanter G D, Taylor C P, et al. Enatioseleetive synthesis of PD144723- A potent stereospecific anticonvulsant. Bioorganic & Medicinal Chemistry Letters, 1994,4(6) :823-826.
  • 6Hoekstra M S, Sohieray D M, Schwindt M A, et al. Chemical development of CI-1008, an enantiomerically pure anticonvulsant. Organic Process Research & Development, 1997, 1 ( 1 ) :26-38.
  • 7Bryans J S, Chessum N E A, Huther N, et al. Metal-catalysed radical cyclisations leading to N-heterocycles: new approaches to gabapentin and pulchellalactam. Tetrahedron, 2003, 59 ( 33 ) : 6221-6231.
  • 8Grote T M, Huckabee B K, Mulhern T, et al. (S)-3- (Aminomethyl)-5-methyl hexanoic acid prepn. - useful as anticonvulsant, in process that does not require expensive reagents or low temps. US, WO 9640617-A. 1996.
  • 9Burns M P, Weaver J K, Wong J W, et al. Preparation of cyanocarboxylic acid, useful to synthesize e. g. pregabalin, comprises contacting succinonitrile with an enzyme catalyst having nitrilase activity in a reaction medium and recovering (3S) isomer. US, WO 2005100580-A1. 2005.
  • 10Martinez C A, Hu S, Dumond Y, et al. Development of a chemoenzymatic manufacturing process for pregabalin. Organic Process Research & Development, 2008, 12 (3) :392-398.

同被引文献12

  • 1Lauria - Homer B A, Pohl R B. Pregabalin : a new anxiolytic [ J ]. Expert Opin. Invest Drugs, 2003, 12(4) :663 -672.
  • 2Charlotte M. The anticonvulsants market [ J ]. Nat. Rev. Drug Discovery, 2010, 9(4) :265 -266.
  • 3Aboul - Enein H Y, Wainer I W. The Impact of Stereochemistry on Drug Development and Use [ M ]. New York, John Wiley & Sons. Inc, 1997 : 214 - 220.
  • 4BurkMJ, DeKoningPD, GroteTM, eta|. Anenantioselectivesynthesisof (S) - ( + ) - 3 - amino - methyl - 5 - methylhexanoic acid via asymmetric hydrogenation[J]. Journal of Organic Chemistry, 2003, 68(14) :5731 -5734.
  • 5Yuen, P W, Kanter, G D, Taylor, C P, et al. Enatioselective synthesis of PD144723 - A protent stereospecific anticonvulsant [ J ] . Bioorg. Med. Chem. Lett, 1994, 4(6):823-826.
  • 6Bryans J S, Chessum N E A, Huther N, et al. Metal - catalysed radical cyclisations leading to N - heterocycles : new approaches to gabapentin and pulchellalactam[ J ]. Tetrahedron, 2003, 59 ( 33 ) : 6221 -6231.
  • 7Martinez C A, Hu S, Dumond Y, et al. Development of a chemoenzymatic manufacturing process for pregabalin [ J ]. Organic Process Research & Development, 2008, 12 (3) :392 -398.
  • 8Grote T M, Huckabee B K, Mulhem T A, et al. (S) -3 - (Aminomethyl) -5 -methyl hexanoic acid prepn. -useful as anticonvulsant, in process that does not require expensive reagents or low temps. : US, WO 9640617 - A1 [ P], 1996 - 12 - 19.
  • 9Hedvati L, Fishman A. The use of enzymatic resolution for the preparation of intermediates of pregabalin: US, WO 2007143113 - A2 [P], 2007 - 12 - 13.
  • 10Lie F, Chen Y Z, Wang Z S, et al. Enantioselective benzylichydroxylation of indan and tetralin with Pseudomonas monteilii TA - 5 [ J ]. Tetrahedron Asymmetry, 2009, 20 (10) : 1206 - 1211.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部